Search

Smith & Nephew PLC

Lezárt

1,265 -0.04

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

1263.5

Maximum

1275.5

Fő mutatók

By Trading Economics

Bevétel

296M

Értékesítés

3B

P/E

Szektor átlag

30.5

24.036

Egy részvényre jutó nyereség

0.429

Osztalékhozam

3.07

Profit margin

9.895

Munkavállalók

17,000

EBITDA

723M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+15.67% upside

Osztalékok

By Dow Jones

Osztalékhozam

Szektor átlag

3.07%

4.19%

Következő eredményjelentés

2026. márc. 2.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

1.6B

11B

Előző nyitás

1265.04

Előző zárás

1265

Smith & Nephew PLC Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. febr. 8. 23:57 UTC

Piaci beszéd

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

2026. febr. 8. 23:47 UTC

Piaci beszéd

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

2026. febr. 8. 23:43 UTC

Piaci beszéd

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

2026. febr. 8. 23:34 UTC

Piaci beszéd

Global Forex and Fixed Income Roundup: Market Talk

2026. febr. 8. 23:34 UTC

Piaci beszéd

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

2026. febr. 8. 23:26 UTC

Piaci beszéd

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

2026. febr. 8. 22:55 UTC

Eredményjelentés

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

2026. febr. 8. 22:55 UTC

Eredményjelentés

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

2026. febr. 8. 22:55 UTC

Eredményjelentés

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

2026. febr. 8. 22:55 UTC

Eredményjelentés

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

2026. febr. 8. 22:55 UTC

Eredményjelentés

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

2026. febr. 8. 22:55 UTC

Eredményjelentés

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

2026. febr. 8. 21:43 UTC

Piaci beszéd

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

2026. febr. 8. 21:16 UTC

Piaci beszéd

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

2026. febr. 8. 21:15 UTC

Piaci beszéd

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

2026. febr. 7. 09:20 UTC

Piaci beszéd

Financial Services Roundup: Market Talk

2026. febr. 7. 09:20 UTC

Piaci beszéd

Basic Materials Roundup: Market Talk

2026. febr. 7. 05:15 UTC

Piaci beszéd

Global Commodities Roundup: Market Talk

2026. febr. 7. 02:46 UTC

Felvásárlások, összeolvadások, átvételek

Big Money, High Anxiety -- Barrons.com

2026. febr. 6. 21:50 UTC

Piaci beszéd

Basic Materials Roundup: Market Talk

2026. febr. 6. 21:50 UTC

Piaci beszéd

Financial Services Roundup: Market Talk

2026. febr. 6. 21:40 UTC

Felvásárlások, összeolvadások, átvételek

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

2026. febr. 6. 21:22 UTC

Piaci beszéd

Mexico's Inflation Seen Accelerating in January -- Market Talk

2026. febr. 6. 21:17 UTC

Eredményjelentés

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

2026. febr. 6. 21:15 UTC

Piaci beszéd

Global Commodities Roundup: Market Talk

2026. febr. 6. 21:14 UTC

Felvásárlások, összeolvadások, átvételek

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

2026. febr. 6. 21:13 UTC

Eredményjelentés

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

2026. febr. 6. 21:13 UTC

Eredményjelentés

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

2026. febr. 6. 21:04 UTC

Piaci beszéd

Gold Closes Out Volatile Week on Higher Note -- Market Talk

2026. febr. 6. 20:34 UTC

Eredményjelentés

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Smith & Nephew PLC Előrejelzés

Célár

By TipRanks

15.67% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 1,465.5 GBX  15.67%

Magas 1,650 GBX

Alacsony 1,290 GBX

8 Wall Street elemző 12 hónapos célárain alapulva a(z)Smith & Nephew PLC termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

8 ratings

5

Vétel

3

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat